Zymeworks (ZYME) EBITDA Margin (2021 - 2026)
Zymeworks (ZYME) reported EBITDA Margin of 1956.73% for Q1 2026, down 186225.0% on a YoY basis from N/an in Q1 2025, and down 11.46% sequentially from 1755.55% in Q4 2025.
Zymeworks (ZYME) EBITDA Margin (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of EBITDA Margin data on file, last reported at 1956.73% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 186225.0% year-over-year to 1956.73%; the trailing twelve-month figure through Mar 2026 stood at 140.35% (down 658.0% YoY), and the FY2025 full-year result was 87.34%, up 9235.0% from the prior year.
- EBITDA Margin slipped to 1956.73% in Q1 2026, from 1755.55% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 98.28% in Q4 2022 to a low of 3793.63% in Q1 2022.
- A 5-year average of 751.85% and a median of 213.78% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin jumped 371695 bps in 2023 and sank 186225 bps in 2026, its largest moves.
- Tracing ZYME's EBITDA Margin over 5 years: stood at 98.28% in 2022, then slumped by 241 bps to 138.37% in 2023, then surged by 48 bps to 71.6% in 2024, then plunged by 2352 bps to 1755.55% in 2025, then declined by 11 bps to 1956.73% in 2026.
- Business Quant data shows ZYME's EBITDA Margin at 1956.73% in Q1 2026, 1755.55% in Q4 2025, and 80.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | -1,956.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,956.73% |
| Dec 31, 2025 | -1,755.55% |
| Sep 30, 2025 | -80.07% |
| Jun 30, 2025 | -1.38% |
| Mar 31, 2025 | -94.48% |
| Dec 31, 2024 | -71.60% |
| Sep 30, 2024 | -213.78% |
| Jun 30, 2024 | -222.87% |
| Mar 31, 2024 | -376.89% |
| Dec 31, 2023 | -138.37% |
| Sep 30, 2023 | -201.36% |
| Jun 30, 2023 | -772.84% |
| Mar 31, 2023 | -76.68% |
| Dec 31, 2022 | 98.28% |
| Sep 30, 2022 | -1,914.03% |
| Jun 30, 2022 | -1,209.54% |
| Mar 31, 2022 | -3,793.63% |
| Dec 31, 2021 | -510.61% |
| Sep 30, 2021 | -1,387.12% |